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We report the case of a 3-year-old boy with urinary tract malformation (left sided stenosis of the ureteropelvic junction) which
was precipitating factor for ensuing nephrolithiasis of the left kidney during the therapy with ceftriaxone. The treatment with
spasmolytics was initiated, together with the forced parentheral hydration. After 3 weeks, there was no evidence of calculi in the
urinary tract.
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1.Introduction
Nephrolithiasis is a condition characterized by the formation
of crystallized material in the urinary system [1]. The
occurrence of urolithiasis is most signiﬁcantly inﬂuenced by
metabolic disorders, urinary tract obstruction with urine
stasis and urinary tract infection [1–3].
Ceftriaxone is a third generation cephalosporin, the
broad spectrum antibiotic with a long plasma half life. It is
widelyusedtotreatinfectionsduringchildhood.Ceftriaxone
is primarily eliminated via kidneys (33–67%), with the
remainder eliminated via biliary system. Ceftriaxone may
bind calcium and form insoluble precipitates leading to
biliary pseudolithiasis and nephrolithiasis [4–6].
The authors report the case of a 3-year-old boy with uri-
nary tract malformation (left-sided stenosis of the uretero-
pelvic junction) who developed nephrolithiasis of the left
kidney during ceftriaxone therapy.
2.CaseReport
A 3-year-old boy was hospitalized in our department with
the diagnosis of Henoch-Sch¨ onlein purpura (HSP). The
symptoms started 12 days before the admittance with
fever, throat, and middle ear infection. He was treated
with antibiotics (amoxicillin/clavulanic acid). On the third
day of therapy, he presented, at ﬁrst individual, and later
generalizedpurpuriclesionsonthelowerextremities.Hewas
initially hospitalized in the regional hospital where he was
treated with penicillin. The skin lesions continue to spread,
with the occurrence of ankle joints edemas as well as the
blood-stained mucus stool. The boy was ﬁnally referred to
our department for further treatment.
There was no evidence of previous more severe diseases
orthediseasesofurinarytract.Familyhistorywasnegativein
concern to nephrolithiasis and any other hereditary disease.
Physical examination conﬁrmed afebrile boy (body
weight 15kg, height 95cm) with partially generalized pal-
pable purpura on the gluteus and lower extremities. Also,
edemas on both ankle joints and feet, as well as of eyelids
were present. Deep palpation of the abdomen did not elicit
pain. Physical ﬁndings of other systems were normal.
Laboratory analyses revealed positive acute phase reac-
tants and normal basic biochemical and immunologic
analyses. The fecal occult blood test in the stool was
positive on several occasions. The coproculture was negative.
Urine ﬁnding was normal. Initial ultrasonography (US)
of the abdomen and urinary tract: dimensions of the left
kidney-70 × 36mm, parenchima thickness-9.6mm, with
hydronephrosis-17 × 20mm. The US ﬁndings of the right2 Case Reports in Medicine
kidney and other US ﬁndings were normal. Immediately
upon the admittance, treatment with corticosteroid ther-
apy started-methylprednisolone 1mg/kg/day. On the third
day of treatment the boy was subfebrile; the chest X-ray
revealed right pneumonia so the therapy with ceftriaxone
100mg/kg/day was initiated. The entire time the boy was in
a good general condition, afebrile during the further course
of the disease, well hydrated. On the 6th day of ceftriaxon
treatment, the boy complained of having an intensive pain
in the abdomen and vomited several times. Mild tenderness
and rigidity in the whole abdomen region was present.
The native X-ray of abdomen did not show urolithiasis.
US of the abdomen and urinary tract showed left-sided
hydronephrosis-38 × 37mm and presence of calculi in the
calices of the inferior pole of the left kidney 15.5mm, and
interpolarly sized 6.5mm (Figure 1). In the ureteropelvic
junction, the calculus sized 6.5mm was visualized. Other
US ﬁndings were normal. During the US examination,
the calculi were seen to disintegrate into sand which was
accumulating in the bladder. The chemical analysis of
the calculus has not been performed because of technical
problems.
Venous blood gas analysis and the electrolythes level
and cystine level in random urine specimen were within
normal range. Urine culture was negative. Urine sediment
was normal, without hematuria. The ceftriaksone therapy
was stopped immediately. The treatment with spasmolytics
wasinitiated, togetherwiththeforcedparentheralhydration.
Following the administered therapy the boy stopped to com-
plain of abdominal pain and had no further symptoms until
theendofhospitalisation.ThesuccessiveUSexaminationsof
the urinary tract conﬁrmed the calculi size reduction within
thekidney,and3weeksfollowingtheinterruptedceftriaxone
therapy,therewerenoevidenceofcalculiintheurinarytract,
whereas the initially diagnosed left kidney hydronephrosis
persisted. Simultaneously, signs of regression of the basic
disease—HSPwerenoted.Inthefurthercourseofthedisease
and during control examinations, the patient underwent the
intravenous urography which conﬁrmed the presence of left
kidney stenosis of the ureteropelvic junction.
3. Discussion
Clinical studies suggest that ceftriaxone can lead to a
reversible precipitation (on US, the calculi present a pos-
terior acoustic shadow) in the gall bladder resembling the
cholelithiasis. This complication is called a biliary pseu-
dolithiasis or a reversible cholelithiasis. A prospective study
showed biliary pseudolithiasis in 25–45% of patients who
were treated with ceftriaxone [4, 5, 7].
Up to now, there were about 10 reports published
on ceftriaxone-induced nephrolithiasis. Ceftriaxon is an
anion and, when drug concentrations in blood are high,
these anions can bind with calcium ions to form insoluble
complexes that precipitate in the biliary system. It appears
that stones can form in the same way in the renal collecting
system [5, 8]. All described calculi were of small dimensions
(a few mm), whereas Mohkam have recently reported a
Figure 1: Calculi in the calices of the inferior pole of the left kidney
15.5mm, and interpolarly sized 6.5mm
case of a 3-year-old child presented with the calculi in
both kidneys sized 10 and 15mm [9]. In most reports, the
ceftriaxone-induced nephrolithiasis occurred during 8–10
days of treatment, with the doses of 50 to 100mg/kg/day.
Shortly after the interruption of the ceftriaxone therapy,
usually 5 days to 3 weeks, rarely after a longer time, the
calculi were eliminated both from the urinary tract and the
gall bladder, [8–12].
In the case of our patient, a complete elimination of the
calculi occurred after 3 weeks of the therapy interruption.
Some authors reported more diﬃcult elimination of the
calculi from the inferior pole of kidney which could be
either prolonged or impossible [13]. Our patient had a
calculus localized in the lower pole of the left kidney, but
nevertheless it has been eliminated very quickly. Perhaps
the intensive parentheral hydration associated with the
administered spasmolytics (the other authors did not report
treatmentprocedureadministeredinthisprotocol)ledtothe
prompt elimination of the calculus from that region of the
kidney.
It is thought that the risk factors leading to ceftriaxone-
induced nephrolithiasis comprise a positive family history,
high doses of ceftriaxone (over 2g/day), quick application
of the drug, dehydration, together with the administration
of nephrotoxic drugs, whereas some authors believe that
metabolic disorders, such as hypercalciuria and hypocitra-
turia could also be metabolic factors favoring crystallization
of calcium ceftriaxonate. Essentially, the ceftriaxone-induced
urolithiasis is self-limited without long-term complications
[1–3, 13, 14].
Our patient received drug doses of 100mg/kg/day. It is
also thought that high doses of the drug can lead to lithiasis,
but this problem can also occur at a normal dose levels.
Perhaps higher doses of the drug lead to larger size calculi
[6]!?
Mohkam analyzed US ﬁndings in 284 children who
were receiving ceftriaxone for pyelonephritis. At the end of
the treatment, 1.4% of the children were presented with
the cefrtiaxone-induced urolithiasis [9]. Biner reported that
0.6%ofchildrentreatedbyceftriaxonedevelopedurolithiasis
and 10% developed biliary pseudolithiasis [15]w h e r e a sCase Reports in Medicine 3
Avci reported on 7.8% children with ceftriaxone-induced
nephrolithiasis [6].
The predisposing factors which might have led to the
development of urolithiasis in our patient were urinary
tract malformation (left-sided stenosis of the ureteropelvic
junction), as well as the corticosteroid therapy (although
laboratory analyses did not prove hypercalciuria). In two
large studies, Mohkam et al., and Avci et al., did not diag-
nose urinary tract malformation in patients with detected
ceftriaxon-induced nephrolitiasis [6, 9].
Finally, it can be concluded that the treatment with
ceftriaxone requires US monitoring of the urinary tract
and abdomen as well as the adequate hydration of the
child. A special attention has to be paid to the children
who have some predisposing factors for the development of
urolithiasis.
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